Published in Clin Med Insights Cardiol on July 23, 2013
The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view. Med Devices (Auckl) (2014) 0.76
Localization of in-stent neoatherosclerosis in relation to curvatures and bifurcations after stenting. J Thorac Dis (2016) 0.75
Neoatherosclerosis after Drug-Eluting Stent Implantation: Roles and Mechanisms. Oxid Med Cell Longev (2016) 0.75
Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study. Tex Heart Inst J (2016) 0.75
Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med (2009) 17.17
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med (2003) 13.29
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med (2002) 12.84
A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature (1994) 11.50
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet (2007) 7.61
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol (2006) 6.07
Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med (2007) 4.95
Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet (2010) 4.87
A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet (2009) 3.55
Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med (2010) 3.27
Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol (2011) 2.85
Coronary revascularization trends in the United States, 2001-2008. JAMA (2011) 2.81
Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA (2008) 2.59
Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet (2011) 2.54
Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol (2003) 2.53
Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol (2008) 2.45
Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation (2001) 2.34
Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J (2009) 1.81
Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med (2010) 1.70
Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter Cardiovasc Interv (2003) 1.64
Trends in coronary revascularization in the United States from 2001 to 2009: recent declines in percutaneous coronary intervention volumes. Circ Cardiovasc Qual Outcomes (2011) 1.51
Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation (2004) 1.48
Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial. Catheter Cardiovasc Interv (2010) 1.43
Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). JACC Cardiovasc Interv (2009) 1.05
Initial clinical experience with an everolimus eluting platinum chromium stent (Promus Element) in unselected patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Int J Cardiol (2012) 0.91
Randomized comparison of everolimus- and paclitaxel-eluting stents: pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trials. Eur Heart J (2010) 0.82
Current status of percutaneous coronary intervention with drug-eluting stents in Asia. Circulation (2008) 0.79
Researchers praise drug-eluting stents but appropriate use is still debated. JAMA (2011) 0.77
Cost-effectiveness of everolimus- versus paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization (from the SPIRIT-IV Trial). Am J Cardiol (2012) 0.77
Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. JAMA (2007) 2.10
Expansion of a regional ST-segment-elevation myocardial infarction system to an entire state. Circulation (2012) 1.88
Vascular closure devices: the second decade. J Am Coll Cardiol (2007) 1.84
Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol (2011) 1.69
Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol (2006) 1.56
Periprocedural myocardial infarction in a randomized trial of everolimus-eluting and Paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitions. Circ Cardiovasc Interv (2012) 1.52
Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel. Catheter Cardiovasc Interv (2005) 1.40
The "bladder sign"--an important early marker of retroperitoneal hemorrhage. Catheter Cardiovasc Interv (2011) 1.40
Target lesion revascularization after bare-metal or drug-eluting stents: clinical presentations and outcomes. J Invasive Cardiol (2010) 1.39
Bleeding avoidance strategies. Consensus and controversy. J Am Coll Cardiol (2011) 1.20
Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). J Am Coll Cardiol (2010) 1.06
Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol (2012) 1.01
ABO blood types: influence on infarct size, procedural characteristics and prognosis. Thromb Res (2008) 0.95
Cocaine use is associated with an increased risk of stent thrombosis after percutaneous coronary intervention. Am Heart J (2007) 0.92
Chronic kidney disease and dipstick proteinuria are risk factors for stent thrombosis in patients with myocardial infarction. Am Heart J (2009) 0.86
Impact of routine angiographic follow-up after percutaneous coronary intervention with drug-eluting stents in the SPIRIT III randomized trial at three years. Am J Cardiol (2012) 0.84
Cost-effectiveness of drug-eluting stents versus bare metal stents in clinical practice. Circ Cardiovasc Qual Outcomes (2011) 0.84
Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. EuroIntervention (2011) 0.83
A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. J Am Coll Cardiol (2003) 0.81
Vascular closure device failure: we are getting better but not there yet. JACC Cardiovasc Interv (2012) 0.80
Optimal therapy for ST-segment elevation myocardial infarction: the role of residual thrombus. J Am Coll Cardiol (2011) 0.79
Differences in baseline characteristics and in-hospital outcomes in patients with or without prior stroke undergoing percutaneous coronary intervention. J Invasive Cardiol (2005) 0.78
Derived fibrinogen compared with C-reactive protein and brain natriuretic peptide for predicting events after myocardial infarction and coronary stenting. Am Heart J (2008) 0.78
Conversations in cardiology: bridging antiplatelet therapy before surgery. Catheter Cardiovasc Interv (2014) 0.78
Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial). Am J Cardiol (2011) 0.78
Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials. EuroIntervention (2012) 0.77
Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: the SPIRIT III 4.0 mm registry. Catheter Cardiovasc Interv (2010) 0.77
Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels. Thromb Res (2003) 0.76
Preprocedural white blood cell count and major adverse cardiac events late after percutaneous coronary intervention in saphenous vein grafts. Am J Cardiol (2005) 0.76
Toward better stratification of patients with left main disease: value of clinical and angiographic-derived risk scores. JACC Cardiovasc Interv (2011) 0.75
Fractional flow reserve-guided stent therapy for multivessel disease: taking a closer look. J Am Coll Cardiol (2010) 0.75
Risk scoring systems for PCI: does one size fit all? J Invasive Cardiol (2011) 0.75
Long-term impact of periprocedural bleeding when does it end? J Am Coll Cardiol (2011) 0.75
Superior in-hospital and 30-day outcomes with abciximab versus eptifibatide: a contemporary analysis of 495 consecutive percutaneous coronary interventions. J Invasive Cardiol (2004) 0.75
Safety of abciximab administration during PCI of patients with previous stroke. J Thromb Thrombolysis (2005) 0.75
The comparative safety of bare-metal and drug-eluting intracoronary stents. Expert Rev Med Devices (2010) 0.75
Evaluation of XIENCE V everolimus-eluting and Taxus Express2 paclitaxel-eluting coronary stents in patients with jailed side branches from the SPIRIT IV trial at 2 years. Am J Cardiol (2013) 0.75